



NDA 22145/S-29
NDA 203045/S-7

SUPPLEMENT APPROVAL

Merck Sharp & Dohme Corp.
Attention: Ursula Marek, Pharm.D.
Associate Director, Global Regulatory Affairs
2015 Galloping Hill Road, K-15-3
Kenilworth, NJ 07033

Dear Dr. Marek:

Please refer to your Supplemental New Drug Application (sNDA) dated February 6, 2013, received February 6, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Isentress® (raltegravir potassium) 400 mg, tablet (NDA 22145) and Isentress® (raltegravir potassium) 25 mg and 100 mg chewable tablet (NDA 203045).

We acknowledge receipt of your amendments dated April 17, 2013, July 10, 2013 and July 23, 2013.

These Prior Approval supplemental new drug applications propose the following changes:

- To update ADVERSE REACTIONS, Selected Adverse Events, PATIENT COUNSELING INFORMATION sections of the package insert, and the Patient Information with information regarding rhabdomyolysis, myopathy, or increased serum creatine kinase,
- To update DRUG INTERACTIONS, Table 7 and CLINICAL PHARMACOLOGY, Table 9 with information regarding drug interactions with boceprevir.

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and text for the patient package insert), with the addition of any labeling changes in pending "Changes Being

Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 22145/S-29
NDA 203045/S-7

Page 3

If you have any questions, call Mammah Sia Borbor, M.S., M.B.A., Regulatory Project Manager, at (301) 796-7731 or (301) 796-1500.

Sincerely,

{See appended electronic signature page}

Kendall Marcus, MD
Deputy Director of Safety
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

KENDALL A MARCUS
08/05/2013